Skip to content

YNIOS Pharma

Active
Private limited company·Vervaardiging van parfums en toiletartikelen· 4 yrs active
Chemin de l'Yerne(VER) 6C ·4537 Verlaine, Belgium
BE 0783.494.239
Watch Print / PDF
Turnover
EBIT margin
Net result€342k
Working capital€-1k
CSV export

Annual accounts & ratios

Source: NBB · 2024
Annual accounts filed on 01-08-2025 with the NBB · fiscal year 2024 · micro
€-200k€0€200k€400kOperating result 2022: €-135k€-135kNet result 2022: €-135k€-135kOperating result 2023: €-196k€-196kNet result 2023: €-196k€-196kOperating result 2024: €343k€343kNet result 2024: €342k€342k202220232024
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts — not a forecast, the extended trend.
growing Equity: growth of ~417.3%/year over 3 fiscal years — indicative, assuming unchanged policy.
€0€500k€1.00M€1.50M2025: €1.02M (€962k – €1.07M)2026: €1.33M (€1.28M – €1.39M)2027: €1.65M (€1.59M – €1.70M)2022: €72k2023: €76k2024: €702k202220232024202520262027
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil–Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

EBITDA
€392k
22–24
Net profit
€342k
22–24
Cash flow
€392k
22–24
Total assets
€970k
+343.7% 22–24
Equity
€702k
+829.9% 22–24
Working capital
€-1k
22–24
Debt
€268k
+87.1% 22–24
Debt ≤ 1y
€268k
+521.2% 22–24
Debt > 1y
€100k
22–24
Current ratio
0.99
-15.7% 22–24
Quick ratio
0.99
-15.7% 22–24
Solvency
72.4%
+109.6% 22–24
Debt / equity
0.38
-79.9% 22–24
ROE
48.7%
22–24
ROA
35.3%
22–24
Interest coverage
326.29
22–24
Figures by fiscal year
Fiscal year2024
Revenue
EBITDA€392k
Net profit€342k
Cash flow€392k
Staff costs
Income taxes
Dividends
Total assets€970k
Equity€702k
Debt€268k
of which ≤ 1y€268k
of which > 1y
Working capital€-1k
Employees (FTE)
Ratios (computed)
2024
Current ratio0.99
Quick ratio0.99
Working capital ratio-0.1%
Solvency72.4%
Debt / equity0.38
Long-term debt ratio
Interest coverage326.29
Gross margin
Net margin
ROA35.3%
ROE48.7%
EBITDA margin
Days sales outstanding
Days payable outstanding
Inventory turnover
Days inventory (DSI)
Balance-sheet composition 2024
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2024
Balance sheet — Assets
TOTAL ASSETS 20/58€970k
Fixed assets 21/28€704k
Intangible fixed assets 21€704k
Current assets 29/58€266k
Amounts receivable within one year 40/41€9k
Cash & bank 54/58€257k
Balance sheet — Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€970k
Equity 10/15€702k
Contributions / capital 10/11€692k
Accumulated profits (losses) 14€11k
Amounts payable 17/49€268k
Amounts payable within one year 42/48€268k
Trade debts payable within one year 44€7k
Income statement
Gross operating margin 9900€393k
Operating result 9901€343k
Financial income 75€236
Financial charges 65€1k
Result before taxes 9903€342k
Net result for the period 9904€342k
Result to be appropriated 9905€342k
You're seeing the latest fiscal year only. Unlock 2 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2024 · computed
76 / 100 Excellent
050100

Unlock the full score breakdown, per-year score history and the indicative credit limit from Starter.

See plans →
Computed by Checked from NBB filings and Belgian State Gazette signals. Indicative — not credit advice.